Synergistic inhibition of SARS-CoV-2 cell entry by otamixaban and covalent protease inhibitors: pre-clinical assessment of pharmacological and molecular properties

SARS-CoV-2, the cause of the COVID-19 pandemic, exploits host cell proteins for viral entry into human lung cells. One of them, the protease TMPRSS2, is required to activate the viral spike protein (S). Even though two inhibitors, camostat and nafamostat, are known to inhibit TMPRSS2 and block cell...

Descripción completa

Detalles Bibliográficos
Autores principales: Hempel, Tim, Elez, Katarina, Krüger, Nadine, Raich, Lluís, Shrimp, Jonathan H., Danov, Olga, Jonigk, Danny, Braun, Armin, Shen, Min, Hall, Matthew D., Pöhlmann, Stefan, Hoffmann, Markus, Noé, Frank
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Royal Society of Chemistry 2021
Materias:
Chemistry
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8494051/
https://www.ncbi.nlm.nih.gov/pubmed/34703545
http://dx.doi.org/10.1039/d1sc01494c

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8494051/
https://www.ncbi.nlm.nih.gov/pubmed/34703545
http://dx.doi.org/10.1039/d1sc01494c

Ejemplares similares